文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

作者信息

Basch Ethan, Dueck Amylou C, Rogak Lauren J, Mitchell Sandra A, Minasian Lori M, Denicoff Andrea M, Wind Jennifer K, Shaw Mary C, Heon Narre, Shi Qian, Ginos Brenda, Nelson Garth D, Meyers Jeffrey P, Chang George J, Mamon Harvey J, Weiser Martin R, Kolevska Tatjana, Reeve Bryce B, Bruner Deborah Watkins, Schrag Deborah

机构信息

Ethan Basch, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Bryce B. Reeve, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Ethan Basch, Lauren J. Rogak, Mary C. Shaw, Narre Heon, and Martin R. Weiser, Memorial Sloan Kettering Cancer Center, New York, NY; Amylou C. Dueck and Brenda Ginos, Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ; Sandra A. Mitchell, Lori M. Minasian, and Andrea M. Denicoff, National Cancer Institute, Rockville, MD; Jennifer K. Wind, Harvey J. Mamon, and Deborah Schrag, Dana-Farber/Partners CancerCare, Boston, MA; Qian Shi, Garth D. Nelson, and Jeffrey P. Meyers, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; George J. Chang, University of Texas MD Anderson Cancer Center, Houston, TX; Tatjana Kolevska, Kaiser Permanente Vallejo Medical Center, Vallejo, CA; and Deborah Watkins Bruner, Emory University, Atlanta, GA.

出版信息

J Clin Oncol. 2018 Sep 11;36(31):JCO2018788620. doi: 10.1200/JCO.2018.78.8620.


DOI:10.1200/JCO.2018.78.8620
PMID:30204536
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6209091/
Abstract

Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed to enable patient reporting of symptomatic adverse events in oncology clinical research. This study was designed to assess the feasibility and resource requirements associated with implementing PRO-CTCAE in a multicenter trial. Methods Patients with locally advanced rectal cancer enrolled in the National Cancer Institute-sponsored North Central Cancer Treatment Group (Alliance) Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and Total Mesorectal Excision trial were asked to self-report 30 PRO-CTCAE items weekly from home during preoperative therapy, and every 6 months after surgery, via either the Web or an automated telephone system. If participants did not self-report within 3 days, a central coordinator called them to complete the items. Compliance was defined as the proportion of participants who completed PRO-CTCAE assessments at expected time points. Results The prespecified PRO-CTCAE analysis was conducted after the 500th patient completed the 6-month follow-up (median age, 56 years; 33% female; 12% nonwhite; 43% high school education or less; 5% Spanish speaking), across 165 sites. PRO-CTCAE was reported by participants at 4,491 of 4,882 expected preoperative time points (92.0% compliance), of which 3,771 (77.2%) were self-reported by participants and 720 (14.7%) were collected via central coordinator backup. Compliance at 6-month post-treatment follow-up was 333 of 468 (71.2%), with 122 (26.1%) via backup. Site research associates spent a median of 15 minutes on PRO-CTCAE work for each patient visit. Work by a central coordinator required a 50% time commitment. Conclusion Home-based reporting of PRO-CTCAE in a multicenter trial is feasible, with high patient compliance and low site administrative requirements. PRO-CTCAE data capture is improved through centralized backup calls.

摘要

相似文献

[1]
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

J Clin Oncol. 2018-9-11

[2]
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Int J Radiat Oncol Biol Phys. 2017-6-1

[3]
Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Transl Behav Med. 2011-3

[4]
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

JAMA Oncol. 2015-11

[5]
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.

JAMA Oncol. 2020-2-13

[6]
Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.

J Patient Rep Outcomes. 2017

[7]
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

J Am Med Inform Assoc. 2019-4-1

[8]
Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.

Int J Radiat Oncol Biol Phys. 2018-6-5

[9]
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Health Qual Life Outcomes. 2016-2-19

[10]
Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.

J Pain Symptom Manage. 2020-5

引用本文的文献

[1]
Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients.

Cancer Med. 2025-4

[2]
Development and Validation of Emoji Response Scales for Assessing Patient-Reported Outcomes.

JCO Clin Cancer Inform. 2025-1

[3]
Impact of immigration background on feasibility of electronic patient-reported outcomes in advanced urothelial cancer patients.

Health Qual Life Outcomes. 2024-12-18

[4]
Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patients.

Qual Life Res. 2024-11

[5]
Irinotecan plus raltitrexed as second‑line chemotherapy for metastatic colorectal cancer: A retrospective study.

Oncol Lett. 2024-6-28

[6]
Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study.

Int J Surg. 2025-1-1

[7]
Challenges in the implementation of electronic systems for patient report of symptoms in oncology: a scoping review.

J Hosp Manag Health Policy. 2021

[8]
Unleashing patient voices: empowering adverse event assessment with complete patient-reported outcomes.

Oncologist. 2024-7-5

[9]
Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review.

Patient. 2024-7

[10]
Avanzando Caminos (Leading Pathways): design and procedures of the Hispanic/Latino Cancer Survivorship Study.

Am J Epidemiol. 2024-7-8

本文引用的文献

[1]
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

JAMA. 2017-7-11

[2]
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Int J Radiat Oncol Biol Phys. 2017-6-1

[3]
Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data.

Expert Opin Drug Discov. 2016-6-16

[4]
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Health Qual Life Outcomes. 2016-2-19

[5]
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Clin Trials. 2016-6

[6]
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

JAMA Oncol. 2015-11

[7]
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

J Natl Cancer Inst. 2014-9-29

[8]
What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials.

J Clin Oncol. 2014-4-7

[9]
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Qual Life Res. 2013-7-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索